Diabetes on the Net is intended for healthcare professionals
This year, the Northern Irish Conference of the PCDS is celebrating its 10th anniversary, and will be doing so in a new virtual format. Building on our heritage we will explore how we will be building a new future for clinical diabetes care in Northern Ireland. Among the topics that we will cover are adapting to COVID-19, how to run a remote clinic, new evidence in diets, and latest advice on managing mental health in the context of diabetes.
As always, you will be able to pick up best-practice tips and hear from the experts on a whole range of clinical issues that are central to high-quality diabetes care.
We very much hope to see you (virtually) there.
Northern Ireland Representatives on the PCDS Committee
Heather Bell, GP, Greenisland
Nigel Campbell, GP, Lisburn
Lesley Hamilton, Diabetes Network Manager and Specialist Dietitian
Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more.
Ask the experts your burning questions through the LIVE Q&A at the end of each session
Log on anytime during the day from the comfort of your own home to view the sessions
Don’t worry if you miss something, all of the content will be available on-demand
Claim 5 CPD points for the full-day virtual conference
09.00 - 09.10
09.10 - 09.40
09.55 - 10.25
10.40 - 11.10
11.25 - 12.05
12.20 - 13.00
13.15 - 13.45
14.00 - 14.30
14.45 - 15.15
15.15 - 15.25
Consultant Diabetologist, Belfast
Consultant Clinical Psychologist, Belfast
Diabetes Nurse Consultant, Somerset
GPwSI in Diabetes and Medical Education, North Berwick
Consultant Endocrinologist and Honorary Senior Lecturer
Diabetes Network Manager, Western Trust
Consultant Podiatrist in Diabetes, Belfast
SAS doctor in General Medicines & Endocrinology, Antrim
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk
Napp Pharmaceuticals Limited
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients
Abbott’s Diabetes Care Division
Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk
Boehringer Ingelheim and Lilly Diabetes Alliance
AgaMatrix manufactures and supplies WaveSense JAZZ™ blood glucose meters, diabetes data management solutions and provides services and support to help you reduce the cost of diabetes care.
With uncompromising accuracy as our cornerstone, we strive to ensure the highest quality diabetes monitoring products and services are supplied at the lowest possible cost.
Find out about our innovative new device, JAZZ™ DoseCoach, the UK’s first evidence-based basal insulin only advisor with built-in blood glucose meter. The device helps patients with type 2 diabetes optimise their once daily insulin glargine dose and is proven to reduce HbA1c.
Boehringer Ingelheim in the UK
We are Boehringer Ingelheim – a different kind of pharmaceutical company. Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.
By working collaboratively, we accelerate the delivery of medical breakthroughs to transform the lives of patients now, and for generations to come.
In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.
We are committed to tackling the challenge of climate change and are a certified carbon neutral organisation. We serve local and global communities through our social impact programme and we support social entrepreneurs who find healthcare solutions for the most vulnerable.
More information can be found at www.boehringer-ingelheim.co.uk
PC-GB-102424 – Date of Preparation August 2020
Eli Lilly and Company Ltd
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.
In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at www.mylan.co.uk.
At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.
Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.
For more information visit novonordisk.co.uk
This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.